'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

Norman Gaylis,Charlotte Both,Lena Lemke,Oliver von Richter,Paul Yamauchi

DOI: https://doi.org/10.1007/s12325-024-02809-w

2024-03-23

Advances in Therapy

Abstract:Hyrimoz ® , (GP2017 [SDZ-ADL]), is a biosimilar to Humira ® (REF-ADL). SDZ-ADL was approved in 2018 by both the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) for the indications of REF-ADL not protected by orphan exclusivity. In 2023, the US FDA and EMA also approved a citrate-free high-concentration formulation (HCF) of SDZ-ADL.

pharmacology & pharmacy,medicine, research & experimental